Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Everolimus to Predict Response in Operable Breast Cancer
NCT00855114Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in breast cancer, sponsored by Masonic Cancer Center. Planned start Jul 2008; status: withdrawn.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00855114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00855114.